Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6421346 | 0.93 | MAPT (0.40) | F10MAPTTP53UTS2RLMNA | |
| SCHEMBL6421409 | 0.92 | F10 (0.39) | F10MAPTPLATKLKB1TP53 | |
| SCHEMBL6424232 | 0.91 | MAPT (0.42) | F10MAPTLMNA | |
| Hydrochloric Acid SCHEMBL6421213 | 0.90 | F10 (0.42) | F10MAPTPLATKLKB1TP53 | |
| SCHEMBL6419853 | 0.88 | F10 (0.37) | F10MAPTPLATKLKB1 | |
| SCHEMBL6420686 | 0.88 | ACHE (0.43) | F10MAPTTP53UTS2RLMNA | |
| SCHEMBL6421802 | 0.87 | PKM (0.38) | F10MAPTLMNA | |
| SCHEMBL6420415 | 0.86 | F10 (0.41) | F10MAPTTP53LMNA | |
| SCHEMBL6424181 | 0.83 | F10 (0.39) | F10MAPTLMNA | |
| SCHEMBL6421356 | 0.83 | F10 (0.40) | F10PLATKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289953-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6784182-B2 | AND FACTOR XA INHIBITORS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-31 | — | — | US | disclosed |
| EP-1289953-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020151724-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2002-10-17 | — | — | US | disclosed |
| WO-2001096304-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151724-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | F10 60/4885MAPT 4835/4885PLAT 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.